About this trial
The study will enroll adult patients scheduled for elective surgery requiring general anesthesia. Participants will be randomly assigned to receive either HRS-9190 for Injection or Cisatracurium. The primary objective is to measure the duration from cessation of the study drug infusion until the recovery of neuromuscular function to a specific level (TOFr ≥ 90%). Secondary objectives include onset time, duration of action, total time of adequate muscle relaxation during surgery, and neuromuscular recovery pattern.. Safety assessments will include monitoring of adverse events, vital signs, laboratory parameters, and other safety indicators throughout the study period. The hypothesis of this study is that HRS-9190 for Injection could provide effective neuromuscular relaxation, with a satisfied safety profile in the target patient population.
Eligibility criteria
Qualifiers
Able and willing to provide a written informed consent
Subjects requiring elective general anesthesia surgery
Meet specified age and body mass index (BMI) criteria
Conform to the ASA Physical Status Classification
Disqualifiers
Scheduled for specific high-risk surgical procedures
History of significant neuromuscular, cardiovascular, respiratory, or neurological disorders
History of conditions affecting drug metabolism or anesthesia risk
Abnormal laboratory values indicating significant clinical abnormalities
Trial design
Treatments tested in this trial
- HRS-9190; under Inhalational Anesthesia
- HRS-9190; under Intravenous Anesthesia
- Cisatracurium (under Inhalational Anesthesia).
- Cisatracurium (under Intravenous Anesthesia)